Biosimilar Drug Sales

Biosimilar Drug Sales Market Outlook

The global biosimilar drug sales market is projected to reach approximately USD 60 billion by 2035, growing at a compound annual growth rate (CAGR) of around 20% during the forecast period from 2025 to 2035. This significant growth is driven by several factors, including the increasing prevalence of chronic diseases, rising healthcare costs, and the patent expiration of several biologic medications. The growing demand for more affordable therapeutic options, coupled with advancements in biotechnology and regulatory support for biosimilars, is expected to propel market expansion. Furthermore, the growing awareness and acceptance of biosimilars among healthcare professionals and patients play a critical role in fostering market growth. Increased investments in research and development, alongside strategic partnerships within the industry, further enhance the market landscape and offer immense growth opportunities.

Growth Factor of the Market

The biosimilar drug sales market is primarily driven by the rising incidence of chronic diseases such as cancer, diabetes, and autoimmune disorders, necessitating effective treatment options that are both accessible and affordable. As patents for several blockbuster biologics expire, there is a surge in the availability of biosimilars, leading to increased competition and reduced drug prices. Additionally, supportive government regulations and guidelines aimed at promoting the development and approval of biosimilar drugs have bolstered market growth. Increased healthcare expenditure across various regions, particularly in developing economies, further emphasizes the need for cost-effective treatments. Furthermore, the growing acceptance of biosimilars among healthcare providers and patients is contributing significantly to the market's expansion, as biosimilars are often seen as viable alternatives to established biologics.

Key Highlights of the Market

• The market is expected to grow at a CAGR of around 20% from 2025 to 2035.
• Increasing prevalence of chronic diseases boosts demand for biosimilars.
• Supportive regulatory frameworks enhance market accessibility.
• Significant investments in R&D drive competitive advancements.
• The growing acceptance and awareness among healthcare providers and patients contribute to market growth.

By Product Type

Monoclonal Antibodies:

Monoclonal antibodies represent one of the most significant categories within the biosimilars market. These therapeutic proteins are engineered to bind to specific targets, such as antigens on cancer cells, effectively treating a variety of cancers and inflammatory diseases. As several monoclonal antibodies have lost patent protection, biosimilars in this category are witnessing increased adoption due to their cost-effectiveness compared to their reference products. The growing pipeline of monoclonal antibody biosimilars provides healthcare providers with more treatment options, further pushing the market growth in this segment.

Insulin:

The insulin biosimilars segment is experiencing substantial growth owing to the rising global incidence of diabetes. With the World Health Organization pointing to an alarming increase in diabetes cases, there is a pressing demand for affordable insulin options. Biosimilar insulins offer a cost-effective alternative to traditional insulin therapies without compromising on efficacy or safety. As healthcare systems worldwide seek to control costs while improving diabetic care, the market for biosimilar insulin products is poised for significant expansion, driven by both patient and provider demand.

Erythropoietin:

Biosimilars of erythropoietin (EPO) are gaining traction primarily due to their effectiveness in treating anemia, particularly in patients undergoing chemotherapy or those with chronic kidney disease. The patent expirations for major EPO products have led to the entry of several biosimilars, which provide a more affordable treatment option for patients. This segment's growth is further supported by the rising awareness of the benefits of biosimilars among healthcare professionals and patients, coupled with the continuous clinical validation of these products as effective therapeutic alternatives.

Human Growth Hormone:

Biosimilars of human growth hormones are primarily used in treating growth hormone deficiency conditions. The increase in childhood and adult growth hormone deficiencies has driven the demand for these biosimilars. As original human growth hormone products face patent expirations, the introduction of biosimilar options is expected to widen access to treatment, especially in regions with high healthcare costs. This segment's growth reflects the broader trend of seeking viable, cost-effective alternatives to traditional biologics in the healthcare landscape, offering a promising avenue for market expansion.

Granulocyte Colony-Stimulating Factor:

Biosimilars of granulocyte colony-stimulating factors (G-CSF) play a crucial role in treating neutropenia, especially among cancer patients undergoing chemotherapy. The increasing incidence of cancer globally underpins the demand for G-CSF biosimilars, which offer a more affordable treatment alternative while ensuring patient safety and efficacy. As healthcare providers strive to manage costs and improve patient outcomes, the G-CSF biosimilars segment is positioned for strong growth, reflecting the overarching trend toward integrating biosimilars into standard care protocols.

By Application

Oncology:

The oncology segment is a prominent application area for biosimilars, driven by the rising number of cancer cases worldwide. Biosimilars in the oncology space enable healthcare providers to offer effective treatments at a lower cost, enhancing patient access to essential therapies. As several biologic oncology drugs face patent expiration, the introduction of biosimilars offers a parallel pathway for patients to receive comparable therapies without financial burden. This segment's growth reflects the overall increase in cancer prevalence, pushing the demand for alternative treatments to meet patient needs.

Chronic Diseases:

Biosimilars are increasingly recognized for their role in managing chronic diseases, particularly conditions such as diabetes and rheumatoid arthritis. The need for long-term treatment options to manage these diseases drives the demand for cost-effective alternatives to traditional biologics. As healthcare systems strive to balance treatment effectiveness with cost considerations, the chronic diseases segment is expected to see substantial growth in biosimilar adoption, aligning with the broader trend of enhancing patient care while controlling healthcare expenditures.

Autoimmune Diseases:

The treatment of autoimmune diseases, including rheumatoid arthritis and psoriasis, is a significant application area for biosimilars. With the increasing prevalence of these diseases, the demand for effective and affordable treatment options has surged. Biosimilars provide a more economical alternative to established biologics, facilitating improved access to therapies for patients. The growth of this segment is also supported by positive clinical trial outcomes and increasing physician awareness of biosimilars as viable treatment options for managing autoimmune conditions.

Blood Disorders:

In the realm of blood disorders, biosimilars play a crucial role in providing therapies for conditions such as anemia and other hematological issues. The rising incidence of blood disorders, coupled with the need for effective and affordable treatments, underlines the importance of biosimilars in this segment. The availability of biosimilars enables patients to receive timely and effective care, thereby improving overall treatment outcomes. This segment is expected to expand as more biosimilars gain approval and enter the market, providing essential options for healthcare providers and patients alike.

Growth Hormone Deficiency:

Biosimilars addressing growth hormone deficiency are witnessing growth due to the increasing diagnosis of this condition in both children and adults. The need for effective therapies that promote normal growth and development has led to a demand for affordable biosimilar options. The market is poised for expansion as healthcare providers increasingly recognize the benefits of biosimilars in treating growth hormone deficiency, alongside the rising number of patients seeking treatment. This segment reflects the broader trend of incorporating biosimilars into standard treatment protocols to enhance patient care and access.

By Distribution Channel

Hospital Pharmacies:

Hospital pharmacies serve as a critical distribution channel for biosimilars, particularly for inpatient care and specialized treatment settings. These facilities often have direct access to patients in need of immediate treatment, making them suitable for administering biosimilars, especially those used in oncology and chronic disease management. The growth of this distribution channel is expected to continue as hospitals increasingly adopt biosimilars, driven by the need to provide cost-effective therapies while ensuring high-quality patient care. Additionally, hospital pharmacists play a significant role in educating healthcare providers about the benefits and efficacy of biosimilars, further enhancing adoption rates.

Retail Pharmacies:

Retail pharmacies are vital to the distribution of biosimilars, serving as accessible locations for patients seeking outpatient treatments. The growing adoption of biosimilars is prominent in retail settings, where patients often prefer obtaining medications from familiar sources. With increasing patient awareness and demand for cost-effective treatments, retail pharmacies are witnessing an uptick in biosimilar sales, particularly for chronic disease therapies. The collaboration between pharmaceutical companies and retail pharmacies to enhance stock availability and patient education is also expected to bolster this distribution channel’s growth.

Online Pharmacies:

Online pharmacies have emerged as a convenient alternative for distributing biosimilars, particularly among tech-savvy consumers who prioritize ease of access to medications. The increasing acceptance of e-pharmacy platforms has opened new avenues for the purchase of biosimilars, especially as patients seek to avoid long wait times at traditional pharmacies. This distribution channel's growth is supported by regulatory frameworks that facilitate the safe online sale of pharmaceuticals, along with the growing trend of telemedicine, which enhances patient engagement in managing their health. As online pharmacies continue to expand their offerings, the biosimilars market is likely to benefit from significant growth in this segment.

Specialty Clinics:

Specialty clinics play an essential role in the distribution of biosimilars, especially for complex conditions such as cancer and autoimmune diseases that require specialized treatment. These clinics often have direct interaction with patients, enabling healthcare providers to guide patients in their treatment choices, including the use of biosimilars. The growth of specialty clinics is expected to continue as more healthcare providers become familiar with the efficacy of biosimilars and the cost-saving benefits they offer. As patient-centered care becomes increasingly important, specialty clinics are well-positioned to enhance the adoption of biosimilars through personalized treatment plans.

Drug Stores:

Traditional drug stores represent a fundamental distribution channel for biosimilars, catering to the general population seeking various medications. As patients become more aware of biosimilars and their benefits, the demand for these products in drug stores is expected to rise. Collaborations between pharmaceutical companies and drug store chains to promote patient education about biosimilars can significantly enhance sales in this distribution channel. The convenience of drug stores, combined with the growing acceptance of biosimilars, is likely to drive further growth in this segment, allowing more patients to access effective and affordable therapies.

By Ingredient Type

Filgrastim:

Filgrastim is a biosimilar used primarily for the treatment of neutropenia, particularly in patients undergoing chemotherapy. The growing prevalence of cancer and the associated need for effective treatment options have led to increased demand for filgrastim biosimilars. As the original products face patent expiration, the market is poised for growth with the introduction of cost-effective alternatives that maintain safety and efficacy. Filgrastim biosimilars not only improve patient access to necessary therapies but also contribute to overall healthcare cost savings, making them a vital component of the biosimilars landscape.

Infliximab:

Infliximab is a biosimilar primarily used in the treatment of autoimmune diseases such as rheumatoid arthritis and Crohn's disease. The high prevalence of these conditions drives the demand for effective therapies, and infliximab biosimilars provide a more affordable option for patients. As healthcare providers increasingly recognize the benefits of biosimilars, infliximab's market share is expected to grow, particularly as it becomes more widely accepted as a standard treatment choice. This segment's growth is indicative of the broader trend toward integrating biosimilars into treatment regimens for chronic and complex diseases.

Etanercept:

Etanercept biosimilars are used in the management of autoimmune conditions and are gaining traction for their efficacy and cost-effectiveness. As the demand for treatments addressing autoimmune diseases rises, etanercept biosimilars offer an affordable alternative that maintains therapeutic effectiveness. The increasing adoption of these products among healthcare providers is likely to bolster market growth, as patients benefit from improved access to treatments that otherwise may be financially prohibitive. The favorable clinical outcomes associated with etanercept biosimilars further enhance their market presence and acceptance.

Adalimumab:

Adalimumab biosimilars represent a significant portion of the biosimilars market due to their widespread use in treating various inflammatory diseases, including rheumatoid arthritis and psoriasis. The introduction of adalimumab biosimilars has been greatly anticipated following the expiration of patent protection on the original product. As more biosimilar options enter the market, patients benefit from lower costs without sacrificing efficacy. The growth of adalimumab biosimilars reflects the broader trend of optimizing treatment access for inflammatory conditions while addressing the escalating costs of healthcare.

Rituximab:

Rituximab biosimilars are primarily utilized in the treatment of hematological malignancies and autoimmune disorders. The approval and uptake of rituximab biosimilars have been significant due to the increasing prevalence of conditions like non-Hodgkin lymphoma and rheumatoid arthritis. The availability of lower-cost biosimilar options has made rituximab therapy more accessible to patients, driving the segment's growth. As healthcare providers become more familiar with the benefits of rituximab biosimilars, their adoption is expected to rise, contributing to the overall growth of the biosimilars market.

By Region

The North American biosimilar drug sales market is projected to dominate the global landscape, driven by a combination of high healthcare expenditure and the presence of key pharmaceutical companies. The region is witnessing substantial growth in the adoption of biosimilars, spurred by increasing awareness among healthcare providers and patients, as well as supportive regulatory frameworks that facilitate the entry of biosimilars into the market. The North American market is expected to grow at a CAGR of over 18% during the forecast period, reflecting the robust demand for affordable treatment options across various therapeutic areas.

In Europe, the biosimilar drug sales market is also experiencing significant growth, largely due to the strict regulatory guidelines that promote the development and approval of biosimilars. European countries have been proactive in implementing policies aimed at increasing the uptake of biosimilars, leading to reduced treatment costs and improved patient access. With the rising prevalence of chronic diseases and substantial investments in healthcare systems, the European market is expected to witness a steady increase in biosimilar sales, with overall growth rates expected to mirror those of North America.

Opportunities

The biosimilar drug sales market presents numerous opportunities for growth, particularly as healthcare systems worldwide seek to manage escalating costs while improving patient access to essential therapies. The increasing acceptance of biosimilars among healthcare providers, coupled with heightened patient awareness, creates fertile ground for the expansion of biosimilar offerings across various therapeutic areas. Furthermore, the growing prevalence of chronic diseases and the subsequent demand for affordable treatment options underline the importance of integrating biosimilars into standard care protocols. The development of innovative biosimilar products, particularly targeting unmet medical needs, offers pharmaceutical companies a chance to capture significant market share and drive overall growth in this burgeoning market.

Emerging economies represent a substantial opportunity for biosimilar drug sales, as these markets are poised for rapid expansion due to the increasing healthcare infrastructure and rising patient populations. Pharmaceutical companies venturing into these regions can benefit from the lower cost of biosimilars, making them an attractive option for both healthcare providers and patients. Furthermore, collaborations with local stakeholders and regulatory agencies can facilitate smoother market entry and enhance the adoption of biosimilars. The potential for strategic partnerships and alliances in these markets can enable companies to harness growth opportunities and better serve the needs of patients who require access to effective and affordable therapies.

Threats

While the biosimilar drug sales market appears promising, it is not without its threats. One of the primary concerns is the intense competition among biosimilar manufacturers, which can lead to pricing pressures and reduced profit margins. As numerous companies attempt to capture market share, the aggressive pricing strategies can undermine the perceived value of biosimilars, impacting the overall market's sustainability. Additionally, the complex regulatory landscape and varying approval processes across regions can pose significant challenges for companies looking to introduce new biosimilars. Striking a balance between compliance and rapid market entry remains a critical hurdle that could affect growth trajectories in the sector.

Furthermore, the skepticism surrounding the interchangeability and long-term safety of biosimilars among healthcare professionals and patients can hinder widespread acceptance. Misconceptions or lack of understanding about biosimilars may lead to hesitancy in prescribing or utilizing these products, which could stifle market growth. Overcoming these educational barriers and ensuring clear communication between manufacturers and healthcare providers is essential for fostering confidence in biosimilars. If not adequately addressed, these threats could impact the overall growth potential of the biosimilar drug sales market.

Competitor Outlook

• Amgen Inc.
• AbbVie Inc.
• Teva Pharmaceutical Industries Ltd.
• Sandoz (a Novartis division)
• Celltrion Healthcare
• Pfizer Inc.
• Samsung Bioepis
• Mylan N.V.
• Boehringer Ingelheim
• Roche Holding AG
• Biocon Limited
• Eisai Co., Ltd.
• Hikma Pharmaceuticals Plc
• Fresenius Kabi AG
• Zyduus Cadila

The competitive landscape of the biosimilar drug sales market is marked by the presence of numerous established players and emerging companies striving for market penetration. As the market matures, firms are increasingly focusing on strategic partnerships, mergers, and acquisitions to bolster their product portfolios and enhance market reach. The landscape is characterized by innovation and continued research and development efforts aimed at bringing new biosimilars to market, addressing unmet patient needs, and ensuring sustained competitive advantage. Companies are also investing in educational initiatives to improve awareness and understanding of biosimilars among healthcare providers and patients, which is critical for boosting adoption rates.

Among the leading competitors, Amgen Inc. has a strong portfolio of biosimilars, including products like Amjevita (adalimumab biosimilar) and Mvasi (bevacizumab biosimilar), showcasing their commitment to providing cost-effective therapeutic options. AbbVie Inc. is another significant player in the biosimilars domain, focusing on expanding its biosimilar offerings to cater to various therapeutic indications. Teva Pharmaceutical Industries Ltd. is known for its robust pipeline and strategic partnerships aimed at enhancing its biosimilars portfolio and driving market growth.

Celltrion Healthcare is gaining momentum in the biosimilars market through its innovative approaches and high-quality products, such as Remsima (infliximab biosimilar). The company has garnered a reputation for its commitment to research and development, positioning itself as a leader in the biosimilars space. Similarly, Sandoz, a division of Novartis, is well-regarded for its comprehensive biosimilar portfolio and has made significant strides in enhancing access to treatment through affordable options. With each competitor leveraging its strengths and capabilities, the biosimilars market is poised for continued evolution and expansion.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Mylan N.V.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 AbbVie Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Pfizer Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Zyduus Cadila
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Biocon Limited
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Eisai Co., Ltd.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Samsung Bioepis
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Roche Holding AG
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Fresenius Kabi AG
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Boehringer Ingelheim
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Celltrion Healthcare
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Hikma Pharmaceuticals Plc
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Sandoz (a Novartis division)
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Biosimilar Drug Sales Market, By Application
    • 6.1.1 Oncology
    • 6.1.2 Chronic Diseases
    • 6.1.3 Autoimmune Diseases
    • 6.1.4 Blood Disorders
    • 6.1.5 Growth Hormone Deficiency
  • 6.2 Biosimilar Drug Sales Market, By Product Type
    • 6.2.1 Monoclonal Antibodies
    • 6.2.2 Insulin
    • 6.2.3 Erythropoietin
    • 6.2.4 Human Growth Hormone
    • 6.2.5 Granulocyte Colony-Stimulating Factor
  • 6.3 Biosimilar Drug Sales Market, By Ingredient Type
    • 6.3.1 Filgrastim
    • 6.3.2 Infliximab
    • 6.3.3 Etanercept
    • 6.3.4 Adalimumab
    • 6.3.5 Rituximab
  • 6.4 Biosimilar Drug Sales Market, By Distribution Channel
    • 6.4.1 Hospital Pharmacies
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies
    • 6.4.4 Specialty Clinics
    • 6.4.5 Drug Stores

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Biosimilar Drug Sales Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Biosimilar Drug Sales market is categorized based on

By Product Type

• Monoclonal Antibodies
• Insulin
• Erythropoietin
• Human Growth Hormone
• Granulocyte Colony-Stimulating Factor

By Application

• Oncology
• Chronic Diseases
• Autoimmune Diseases
• Blood Disorders
• Growth Hormone Deficiency

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Specialty Clinics
• Drug Stores

By Ingredient Type

• Filgrastim
• Infliximab
• Etanercept
• Adalimumab
• Rituximab

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Amgen Inc.
• AbbVie Inc.
• Teva Pharmaceutical Industries Ltd.
• Sandoz (a Novartis division)
• Celltrion Healthcare
• Pfizer Inc.
• Samsung Bioepis
• Mylan N.V.
• Boehringer Ingelheim
• Roche Holding AG
• Biocon Limited
• Eisai Co., Ltd.
• Hikma Pharmaceuticals Plc
• Fresenius Kabi AG
• Zyduus Cadila